Optimising Intervention Strategies To Reduce The Burden Of Group A Streptococcus In Aboriginal Communities
Funder
National Health and Medical Research Council
Funding Amount
$856,896.00
Summary
Skin sores are highly prevalent in remote Australian Indigenous communities and can lead to invasive infections and rheumatic heart disease. We will develop mathematical models to understand the transmission of skin sores, allowing us to define the optimal extent (household, community, region), timing and triggers for interventions to interrupt transmission. This will guide public health policy in reducing the prevalence of skin sores and scabies, and their accompanying disease burden.
Biofocussed Prostate Cancer RadioTherapy (BiRT): A Personalised Approach To Delivering The Right Dose To The Right Place
Funder
National Health and Medical Research Council
Funding Amount
$753,565.00
Summary
We propose a new approach to treating prostate cancer with radiotherapy to move from the standard whole prostate treatment to a personalised treatment that varies radiation intensity throughout the prostate. We will mathematically combine features that influence radiotherapy effect from advanced imaging, clinical and biopsy information. This model will map out the radiotherapy dose required at each part of the prostate, to maximise killing of the cancer whilst minimising harm to normal tissue
Modelling The Impact Of Strategies To Control Gonorrhoea And Minimise The Threat Of Antimicrobial Resistance In Remote Indigenous And Other High Risk Populations
Funder
National Health and Medical Research Council
Funding Amount
$467,079.00
Summary
Gonorrhoea is a serious public health issue in Australia. Notification rates are disproportionately high among Aboriginal and Torres Strait Islander people and men who have sex with men, and there is evidence of an emerging epidemic in the general heterosexual population. Additionally, available treatments are under threat from resistant strains. We will use mathematical modelling to evaluate strategies for controlling gonorrhoea and for minimising the threat of antimicrobial resistance.
Improving Patient Safety In Radiation Therapy With The Watchdog Real-time Treatment Delivery Verification System
Funder
National Health and Medical Research Council
Funding Amount
$593,742.00
Summary
Radiation therapy is a highly effective cancer treatment with extremely high doses delivered using very complex treatment machines. Unfortunately errors have occurred resulting in cases of patient death and mistreatment. We have developed a novel method to assess the treatment delivery in real-time to prevent errors. The method uses imaging devices that are already present on the treatment machine meaning that this method could have a major impact on patient safety in modern radiation therapy.
Real Time Models To Inform Prevention And Control Of Emerging Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$549,728.00
Summary
This proposed research addresses the need for real-time tracking of emerging infectious diseases (EID), both spatially and temporally, to inform international and national outbreak response teams, aid in the implementation of real-time containment strategies and ultimately the timely control of emerging infectious diseases. Outcomes will directly enhance & inform policy-making and EID preparedness at a national and international level.
Optimising Radiation Therapy Delivery For Cancer Patients Using Daily Image Guidance To Maximize Cure And Reduce Normal Tissue Side Effects
Funder
National Health and Medical Research Council
Funding Amount
$510,968.00
Summary
When using radiotherapy to kill tumours, the radiation beams need to be targeted at the tumour, plus a margin of error around it to ensure that it receives sufficient dose despite uncertainties in its exact location relative to reference points used for beam alignment. Advanced statistical modelling techniques applied to data collected from patients will be used to determine the optimal margin width for individual patients to maximise cancer cure while minimising normal tissue side effects.